logo
Eating ‘Family Style' May Have Set the Stage for Life as We Know It

Eating ‘Family Style' May Have Set the Stage for Life as We Know It

New York Times31-03-2025

For a creature made up of only a single cell, the stentor is a giant. This trumpet-shape organism is among the largest unicellular organisms, stretching as long as a sharpened pencil tip. But sometimes it has a hard time vacuuming up the swimming bacteria and microscopic algae it eats to survive.
New research reveals that stentors, which are part of a group called protists, may address this challenge by eating 'family style.' In a paper published on Monday in the journal Nature Physics, scientists shared the discovery that colonies of stentors can make water flow more quickly around them, helping them suck up more prey.
The new findings suggest that, although they lack neurons or brains, stentors can cooperate with one another.
'These single-cell organisms can do things that we assume are limited to more complex organisms,' said Shashank Shekhar, a biophysicist at Emory University in Atlanta who is the lead author of the new paper. 'They form this higher order structure, like what we do as humans.'
Scientists believe that the ability of single-cell creatures to form groups was a key step that led to the eventual evolution of multicellular life on Earth. And the new findings spotlight the role played by physical conditions — and the interplay of predators and prey — in these cellular collaborations.
In the wild, stentors are found near the surface of ponds. The wider end of their bodies is fringed with ropelike cilia. These cilia can fluctuate in a wavelike pattern to generate water currents that sweep in prey.
To visualize these currents in the lab, Dr. Shekhar put drops of milk alongside stentors in a petri dish and then watched how the liquid flew under a microscope. 'You see them create these swirls around their mouths that are just beautiful,' he said. He compared the movements to the whirling cosmos of van Gogh's 'The Starry Night.'
When food is scarce, stentors usually live alone. But when food is plentiful, they often congregate in writhing clusters. Little work has been done to explore why the protists form these colonies.
Dr. Shekhar and his colleagues first examined the interaction between pairs of stentors. Using microscope video footage, they measured the fluid dynamics as two stentors sucked in food particles in a petri dish.
The videos revealed an odd pattern: The stentors would drift toward each other before moving away, as if repelled by a magnet. 'They constantly rotate between 'I love you, I love you not,'' Dr. Shekhar said.
Further analysis then showed that stentor pairs were often in an unequal union, with one of the protists generating a stronger flow than its neighbor. When they got together, the resulting flow was the combined strength of both creatures. This meant that the weaker stentor benefited from the stronger one.
Such dynamics among the stentors inspire what Dr. Shekhar calls 'promiscuous behavior.' When they gather in colonies, the stentors are constantly pairing with one another to find stronger partners and increase their feeding capabilities. This behavior increases the colony's overall flow velocity, allowing the stentors to siphon in larger, fast-moving prey from farther away, and increase the nutrients consumed by the group's members.
The formation of groups by single-cell organisms to improve survival is viewed as an important early step in the evolution of multicellularity. According to William Ratcliff, an evolutionary biologist at the Georgia Institute of Technology who was not involved in the new paper, once groups of predators like stentors formed, single-cell prey were more susceptible. To survive, the prey often teamed up themselves.
'The improved feeding efficiency by group predators like stentors selects for multicellularity in their prey,' Dr. Ratcliff said. 'If you're a single cell, you're dinner. But if you can form large groups of cells, now you're too big to eat.'
The new findings highlight how physical forces influence biological evolution.
'We always think about genes and chemicals, but there's also a strong underpinning of physics in the development of multicellular life,' Dr. Shekhar said. 'Even something like the flow of water could have affected evolution.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sussex researchers make world record-breaking discovery
Sussex researchers make world record-breaking discovery

Yahoo

time3 days ago

  • Yahoo

Sussex researchers make world record-breaking discovery

Sussex researchers have made a world record-breaking discovery that could revolutionise brain scanning. The team at the University of Sussex has developed a technique to detect tiny electrical fields 100 times more effectively than current methods. This discovery, published in Nature Physics, has the potential to significantly improve applications in healthcare, defence, underwater detection and communication, and geological prospecting. The technique was initially developed to create more powerful quantum computers, but its potential extends far beyond this. Medical experts suggest it could lead to huge breakthroughs in our understanding of mental illness, including in the treatment of depression and epilepsy, through improved and less intrusive brain imaging. The researchers used a single charged atom inside a vacuum system, combined with a measurement technique they invented, to achieve this feat. This has made the technique around 100 times more powerful than was previously possible. However, the discovery has the potential to be one million times more powerful. Professor Winfried Hensinger, director of the Sussex Centre for Quantum Technologies, said: "We have built a machine that makes use of single charged atoms (ions), capable of unprecedented measurement capability. "We have managed to tame some of the very strange phenomena of quantum physics to create a device that can detect low frequency electric fields with unprecedented sensitivity. "And we recently developed a microchip that could enhance this sensitivity even further by yet another 10,000 times. "Using a different ion species with such a chip could enhance sensitivity indeed by a million times." James Stone, professor of psychiatry at Brighton and Sussex Medical School, said: "It is an exciting discovery – with development it could open the way for much less intrusive and more detailed 3D imaging of electrical activity in the brain, giving the potential to detect which parts of the brain are active in real-time, and potentially giving insights into how thoughts and sensations are represented in the brain. "It could potentially lead to huge breakthroughs in our understanding of consciousness, as well as of mental illness, and may even be useful in neurofeedback treatments for mental health conditions such as obsessive compulsive disorder or depression by allowing people to visualise their brain activity and respond directly to it. "It could also be useful in neurological conditions such as epilepsy – detecting regions of abnormal activity in deeper brain regions than would be possible with existing EEG methods."

At-home health tests are here. But they aren't always the best option
At-home health tests are here. But they aren't always the best option

Yahoo

time4 days ago

  • Yahoo

At-home health tests are here. But they aren't always the best option

The doctor is in — the mailbox, that is. You can now do self-administered tests for everything from thyroid function to HIV in the privacy of your own home — and that list continues to grow, as the Food and Drug Administration recently approved the first at-home cervical cancer test. While the tests can make it easier for people to access health care and can be helpful for those who have extreme anxiety about sensitive or invasive medical exams, experts warn that most of the tests cannot replace an actual in-person visit. Here's what doctors say you can test for at home, and when you should make the trek to your physician's office. What kinds of at-home tests are available? There are two kinds at 'at-home tests.' In one type, the patient collects the sample and sends it off to a lab; the new cervical cancer test is like this. The other gives an instant result — think COVID-19 and pregnancy tests. What are the benefits of at-home tests? HIV home-testing kits can improve rates of diagnosing sexually transmitted infections in rural communities and help people who are nervous about going to the doctor to seek a sensitive test, said Dr. Joseph Cherabie, an infectious diseases specialist in St. Louis. 'You really want to get people to care as quickly as possible, but some people could be very anxious about that results as well," Cherabie said. "And they have very negative reactions.' Labs are required to report a positive HIV test, instead of putting the onus on the patient who took the test, Cherabie said, and and, often, the patient is matched up with HIV support services. 'If you are part of a sexual and gender minority community, going to a doctor's office can be full of a lot of historical trauma, and you may prefer to just do testing at home without anyone judging you or asking you invasive questions about your sex life,' Cherabie said. The new cervical cancer test — which tests for strains of human papillomavirus, or HPV — involves a testing swab that's like a tampon, said Dr. Susan Modesitt, a gynecologic oncologist at Emory University in Atlanta. It is not, Modesitt said, a replacement for a Pap smear, the exam in which a metal speculum is inserted in the vagina to scrape cervix cells. A doctor's visit also involves a pelvic exam, a chance to talk about abnormal bleeding — a sign of endometrial cancer — and other symptoms and issues, like menopause or STIs. 'There are so many other reasons to see your doctor and get an exam outside of a cervical cancer screening,' she said. I live in a rural area — can I take an at-home test? Some at-home tests can replace a trip to the doctor's office. That's especially true in rural areas, where it can be difficult to get a colonoscopy. 'The colonoscopy requires a pre-op, and you have to drive maybe 70 miles for it,' said Dr. Steven Furr, board chair of the American Academy of Family Physicians who practices in rural Alabama. 'You get anesthesia. It's actually almost like a surgical procedure in many ways. "So, for a lot of people, that's pretty arduous. That's where an at-home test can come in handy.' But, Furr said, if your test reveals issues, you need to go to your doctor. Plus, patients should always discuss test results with their physician instead of interpreting them on their own, he said. Who shouldn't do at-home tests? If you have symptoms of what you're testing for, go to the doctor. At-home colon cancer tests aren't the right option for people with a history of colon cancer or high-risk conditions, such as inflammatory bowel disease, said Dr. Zachariah Foda, a gastroenterologist at Johns Hopkins. He added that they're also not recommended for people who are having GI symptoms. While there are tests for many things — running anywhere from $15 to $400, depending on what is being evaluated — Furr said it's essential to make sure that your test is FDA-approved so you can better trust the results. 'Anytime we get people involved in their own health care and help them understand what's going on, I think that's a good thing and it gives us a chance to talk,' he said. 'Any kind of screening is better than no screening.' ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content. Devna Bose, The Associated Press Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Yahoo

time27-05-2025

  • Yahoo

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response. ROCHESTER, N.Y., May 27, 2025 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and Alzheimer's disease (AD) through the inhibition of Semaphorin 4D (SEMA4D), today announced that it will present new data characterizing the unique mechanism of pepinemab to enhance immune responses to checkpoint therapies in the neoadjuvant setting that are associated with improved pathologic response in patients with head and neck cancer. Lead investigator and collaborator, Conor Steuer, MD from Winship Cancer Center at Emory University, will present results at the 2025 Annual Meeting of Clinical Oncology (ASCO) in Chicago on June 1, 2025. ASCO Conference Information: Date: Sunday, June 1, 2025 Presentation title: Neoadjuvant biomarker trial of pepinemab to enhance nivolumab or ipilimumab activity in resectable head and neck cancer. Abstract 103. Time: 9:45-11:15 AM CST/10:45 AM – 12:15 PM EST. Session Title: Clinical Science Symposium – Turning 'Cold' Tumors 'Hot' Previously reported data from our collaboration with Emory University suggest a crucial role of pepinemab treatment in melanoma patients to facilitate immune cell interactions within highly organized and robust centers of immunity, called tertiary lymphoid structures, or TLS. By blocking the SEMA4D inhibitory signal to Dendritic Cells (DC), pepinemab allows productive, coordinated interactions between SEMA4D+ T cells, key effector cells capable of eradicating tumors, and DC, regulatory cells that promote immune cell interactions within TLS so as to amplify mature T cell responses. New data presented at ASCO will characterize the mechanisms of neoadjuvant treatment with pepinemab in patients with resectable head and neck cancer (HNSCC). Standard of care for these patients often involves toxic chemotherapy and/or radiotherapy, in addition to surgery, which can significantly impact their quality of life. Peri-operative treatment with immunotherapy has recently reported promising and potentially practice-changing results. Certain HNSCC with hot beds of immune cells organized into TLS have been shown to correlate with clinical benefit and positive response to immune checkpoint therapy. However, many HNSCC are considered immunologically 'cold' tumors, due to exclusion of immune cells from tumor and/or high levels of immune suppressor cells, making them resistant to immune checkpoint therapy. Pepinemab has potential to be a major advance for HNSCC patients with cold and resistant disease, with capacity of a well-tolerated and effective treatment that can induce formation and harness the power of TLS to optimize the clinical benefit of immunotherapy. Our data demonstrate that the addition of pepinemab to neoadjuvant immune checkpoint treatments did not compound toxicities, yet it enhanced TLS maturity that correlated with improved pathologic response. Collectively, these results highlight the potential of pepinemab to turn immunologically cold tumors, such as HPV-negative head and neck cancer, into hot immune centers by inducing robust and mature TLS. About PepinemabPepinemab is a humanized IgG4 monoclonal antibody designed to block SEMA4D, which can otherwise bind to plexin-B1 receptors to trigger collapse of the actin cytoskeleton and lead to loss of homeostatic functions of dendritic cells in immune tissue and of astrocytes and other glial cells in the brain. Pepinemab appears to be well-tolerated with a favorable safety profile in multiple clinical trials in different cancer and neurological indications. About Vaccinex Inc. Vaccinex, Inc. is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The Company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents infiltration and activation of immune cells in tumors and triggers damaging inflammation in neurodegenerative diseases. In oncology, pepinemab is also being evaluated in combination with KEYTRUDA® in the Phase 1b/2 KEYNOTE-B84 study in recurrent or metastatic head and neck cancer (HNSCC) and in combination with BAVENCIO® in a Phase 1b/2 study in patients with metastatic pancreatic adenocarcinoma (PDAC). The oncology clinical program also includes several investigator-sponsored studies in solid tumors including breast cancer and melanoma. We believe pepinemab has also given promising results as a monotherapy in the Phase 1b/2 SIGNAL-AD study in Alzheimer's Disease, and the Company has previously published promising Phase 2 data suggesting a slowing of cognitive decline in Huntington's disease. Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of Merck and Co, Inc. Kenilworth, NJ, USA. Additional information about the study is available at: KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. BAVENCIO®/avelumab is provided by Merck KGaA, Darmstadt, Germany, previously as part of an alliance between the healthcare business of Merck KGaA, Darmstadt, Germany and Pfizer. Forward Looking StatementsTo the extent that statements contained in this press release are not descriptions of historical facts regarding Vaccinex, Inc. ('Vaccinex,' 'we,' 'us,' or 'our'), they are forward-looking statements reflecting management's current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives with respect to the results and timing of the KEYNOTE-B84 and SIGNAL-AD clinical trials; the use and potential benefits of pepinemab in R/M HNSCC, lung cancer, metastatic pancreatic adenocarcinoma (PDAC) and other indications; the potential for benefits as compared to single agent KEYTRUDA® or BAVENCIO®; expectations with respect to the collaboration of Merck,; and other statements identified by words such as 'anticipate,' 'believe,' 'plans,' 'schedule,' 'being,' 'will,' 'appears,' 'expect,' 'ongoing,' 'potential,' 'promising,' 'suggest', and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause the outcome of our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical studies and clinical trials, that interim and preliminary data may not be predictive of final results and does not ensure success in later clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab, and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, the Company assumes no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled 'Risk Factors' in our previous reports filed with the Securities and Exchange Commission and the other risks and uncertainties described in the Company's 2024 year-end Form 10-K filed with the SEC. CONTACT: Investor Contact Elizabeth Evans, PhD Chief Operating Officer Senior Vice President, Vaccinex, Inc. (585) 271-2700 eevans@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store